These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 21606417)

  • 1. SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer.
    Yang M; Xie W; Mostaghel E; Nakabayashi M; Werner L; Sun T; Pomerantz M; Freedman M; Ross R; Regan M; Sharifi N; Figg WD; Balk S; Brown M; Taplin ME; Oh WK; Lee GS; Kantoff PW
    J Clin Oncol; 2011 Jun; 29(18):2565-73. PubMed ID: 21606417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphisms of the androgen transporting gene SLCO2B1 may influence the castration resistance of prostate cancer and the racial differences in response to androgen deprivation.
    Fujimoto N; Kubo T; Inatomi H; Bui HT; Shiota M; Sho T; Matsumoto T
    Prostate Cancer Prostatic Dis; 2013 Dec; 16(4):336-40. PubMed ID: 23896625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer.
    Harshman LC; Wang X; Nakabayashi M; Xie W; Valenca L; Werner L; Yu Y; Kantoff AM; Sweeney CJ; Mucci LA; Pomerantz M; Lee GS; Kantoff PW
    JAMA Oncol; 2015 Jul; 1(4):495-504. PubMed ID: 26181260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes.
    Wright JL; Kwon EM; Ostrander EA; Montgomery RB; Lin DW; Vessella R; Stanford JL; Mostaghel EA
    Cancer Epidemiol Biomarkers Prev; 2011 Apr; 20(4):619-27. PubMed ID: 21266523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of SLCO2B1 Genotypes With Time to Progression and Overall Survival in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer.
    Wang X; Harshman LC; Xie W; Nakabayashi M; Qu F; Pomerantz MM; Lee GS; Kantoff PW
    J Clin Oncol; 2016 Feb; 34(4):352-9. PubMed ID: 26668348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SLCO1B3 and SLCO2B1 genotypes, androgen deprivation therapy, and prostate cancer outcomes: a prospective cohort study and meta-analysis.
    Rajanala SH; Plym A; Vaselkiv JB; Ebot EM; Matsoukas K; Lin Z; Chakraborty G; Markt SC; Penney KL; Lee GM; Mucci LA; Kantoff PW; Stopsack KH
    Carcinogenesis; 2024 Feb; 45(1-2):35-44. PubMed ID: 37856781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer.
    Sharifi N; Hamada A; Sissung T; Danesi R; Venzon D; Baum C; Gulley JL; Price DK; Dahut WL; Figg WD
    BJU Int; 2008 Aug; 102(5):617-21. PubMed ID: 18537956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of prostate cancer SLCO gene expression with Gleason grade and alterations following androgen deprivation therapy.
    Alsinnawi M; Zhang A; Bianchi-Frias D; Burns J; Cho E; Zhang X; Sowalsky A; Ye H; Slee AE; True L; Porter C; Taplin ME; Balk S; Nelson PS; Montgomery RB; Mostaghel EA
    Prostate Cancer Prostatic Dis; 2019 Dec; 22(4):560-568. PubMed ID: 30890759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer.
    Ross RW; Oh WK; Xie W; Pomerantz M; Nakabayashi M; Sartor O; Taplin ME; Regan MM; Kantoff PW; Freedman M
    J Clin Oncol; 2008 Feb; 26(6):842-7. PubMed ID: 18281655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of SLCO1B3 drives taxane resistance in prostate cancer.
    de Morrée ES; Böttcher R; van Soest RJ; Aghai A; de Ridder CM; Gibson AA; Mathijssen RH; Burger H; Wiemer EA; Sparreboom A; de Wit R; van Weerden WM
    Br J Cancer; 2016 Sep; 115(6):674-81. PubMed ID: 27537383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer.
    Hamada A; Sissung T; Price DK; Danesi R; Chau CH; Sharifi N; Venzon D; Maeda K; Nagao K; Sparreboom A; Mitsuya H; Dahut WL; Figg WD
    Clin Cancer Res; 2008 Jun; 14(11):3312-8. PubMed ID: 18519758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
    Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.
    Ross RW; Xie W; Regan MM; Pomerantz M; Nakabayashi M; Daskivich TJ; Sartor O; Taplin ME; Kantoff PW; Oh WK
    Cancer; 2008 Mar; 112(6):1247-53. PubMed ID: 18293426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Androgen-deprivation therapy in prostate cancer: clinical evidence and future perspectives].
    Pinto F; Calarco A; Totaro A; Sacco E; Volpe A; Racioppi M; D'Addessi A; Bassi PF
    Urologia; 2010; 77(2):71-83. PubMed ID: 20890863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SRD5A gene polymorphism in Japanese men predicts prognosis of metastatic prostate cancer with androgen-deprivation therapy.
    Shiota M; Fujimoto N; Yokomizo A; Takeuchi A; Itsumi M; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
    Eur J Cancer; 2015 Sep; 51(14):1962-9. PubMed ID: 26169017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic polymorphisms in oestrogen receptor-binding sites affect clinical outcomes in patients with prostate cancer receiving androgen-deprivation therapy.
    Huang CN; Huang SP; Pao JB; Hour TC; Chang TY; Lan YH; Lu TL; Lee HZ; Juang SH; Wu PP; Huang CY; Hsieh CJ; Bao BY
    J Intern Med; 2012 May; 271(5):499-509. PubMed ID: 21880074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vitamin D receptor gene variants and clinical outcomes after androgen-deprivation therapy for prostate cancer.
    Pao JB; Yang YP; Huang CN; Huang SP; Hour TC; Chang TY; Lan YH; Lu TL; Lee HZ; Juang SH; Huang CY; Bao BY
    World J Urol; 2013 Apr; 31(2):281-7. PubMed ID: 22193519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen-deprivation therapy and metabolic syndrome in men with prostate cancer.
    Harrington JM; Schwenke DC; Epstein DR; Bailey DE
    Oncol Nurs Forum; 2014 Jan; 41(1):21-9. PubMed ID: 24368236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SLCO1B1, SLCO2B1, and SLCO1B3 polymorphisms and susceptibility to bladder cancer risk.
    Bui HT; Fujimoto N; Kubo T; Inatomi H; Matsumoto T
    Cancer Invest; 2014 Jul; 32(6):256-61. PubMed ID: 24762081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.